Cutaneous toxicities of antiretroviral therapy for HIV Part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors
Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. Journal of the American Academy of Dermatology
(Impact Factor: 4.45).
10/2010; 63(4):549-61; quiz 561-2. DOI: 10.1016/j.jaad.2010.01.061
Antiretroviral medications for the treatment of HIV are common drugs with diverse and frequent skin manifestations. Multiple new cutaneous effects have been recognized in the past decade. Dermatologists play an important role in accurately diagnosing and managing the cutaneous toxicities of these medications, thereby ensuring that a patient has as many therapeutic options as possible for life-long viral suppression. Part I of this two-part series on the cutaneous adverse effects of antiretroviral medications will discuss HIV-associated lipodystrophy syndrome, which can be seen as a result of many antiretroviral medications for HIV, and the specific cutaneous effects of the nucleoside reverse transcriptase inhibitors and protease inhibitors.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.